Cefepime (4th Gen) Injectable (iv/im) Generics - Manufacturers & Suppliers
Maxipime(US & EU)
| Product/Composition:- | Cefepime (4th Gen) Injectable (IV/IM) |
|---|---|
| Strength:- | 1 g, 2 g, 4 g per vial |
| Form:- | Injectable (IV/IM) |
| Reference Brands:- | Maxipime(US & EU) |
| MOQ | As per the manufacturer batch size |
| Get Quote Send Enquiry on WhatsApp | |
Cefepime inhibits bacterial cell wall synthesis by targeting penicillin-binding proteins, causing bacterial lysis. It is effective against multi-drug resistant gram-negative bacteria, including Pseudomonas. Benefits include rapid bacterial eradication, broad-spectrum activity, and use in severe infections like pneumonia and sepsis, especially in hospital settings for critical cases.
Cefepime IV injection is approved in the EU and US for treating severe bacterial infections, including pneumonia, sepsis, and febrile neutropenia. In the EU, brands like Maxipime are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing standards. In the US, FDA approval relies on extensive clinical data; generic formulations are available. Both regions require detailed dossiers, including clinical trial results, quality assurance, and pharmacovigilance plans, for approval and continuous safety monitoring. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We support seamless market access for cefepime injection, ensuring adherence to European and US standards for safe, effective treatment of serious infections.